This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2022-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2026
Title: Mark Chambers - Innovator in Cardiovascular Treatments
Introduction
Mark Chambers is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for cardiovascular diseases. His innovative work has the potential to impact many lives.
Latest Patents
Mark Chambers holds a patent for PCSK9 inhibitors and methods of use thereof. This invention relates to novel heteroaryl compounds of Formula (I) and pharmaceutical preparations thereof. The invention further encompasses methods of treating or preventing cardiovascular diseases, as well as methods for treating sepsis or septic shock, using the novel heterocyclic compounds disclosed in the patent. He has 1 patent to his name.
Career Highlights
Mark Chambers is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca focuses on advancing medical treatments that address critical health issues.
Collaborations
Throughout his career, Mark has collaborated with talented individuals such as Michael H Serrano-Wu and Erica Goldsmith. These collaborations have fostered innovation and contributed to the success of his projects.
Conclusion
Mark Chambers is a dedicated inventor whose work in developing PCSK9 inhibitors showcases his commitment to improving healthcare. His contributions to the field of pharmaceuticals are invaluable and hold promise for future advancements in treating cardiovascular diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile